Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
82878
First IPO Date
December 28, 2007
| Name | Title | Pay | Year Born |
| Belen Garijo Lopez | Chief Executive Officer & Director | 3.98M | 1960 |
| Roy Papatheodorou | Executive Vice President & General Counsel | 0 | 1978 |
| Thomas Kudsk Larsen | Head of Investor Relations & General Medicines | 0 | 1974 |
| Thomas Triomphe | Executive Vice President of Vaccines | 0 | 1974 |
| Madeleine Roach | Executive Vice President & Head of Business Operations | 0 | 1984 |
| Pierre Chancel | Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing | 0 | 1957 |
| Natalie Bickford | Executive Vice President & Chief People Officer | 0 | 1970 |
| Fabrizio Gaudi | Head of Austrian, German & Swiss Operations | 0 | N/A |
| Erik Wallström | Head of Therapeutic Area - Neurology Development | 0 | N/A |
| François-Xavier Roger | Executive Vice President & Chief Financial Officer | 0 | 1962 |
| Olivier Charmeil | Executive Vice President of General Medicines | 0 | 1963 |
Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of innovative therapeutic solutions across North America, Europe, and other international markets. Its operations are organized into three principal segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical division, Sanofi offers a diverse portfolio of specialty care products, including advanced human monoclonal antibodies. These target a range of serious conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare genetic disorders, oncology, and rare blood conditions. The company also provides essential medicines for diabetes, cardiovascular health, and a selection of established prescription drugs. The Vaccines segment delivers crucial immunizations, encompassing pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside a variety of vaccines for adults, including those for influenza, boosters, meningitis, and specific travel or endemic diseases. Sanofi's Consumer Healthcare arm supplies a broad spectrum of over-the-counter products, addressing needs like allergy relief, cough and cold symptoms, pain management, liver support, physical and mental wellness (including probiotics and digestive aids), and nutritional supplements. This segment also includes various topical and skincare solutions, such as daily body lotions, anti-itch treatments, moisturizing creams, and powders for skin conditions like eczema. Beyond its current offerings, Sanofi maintains a robust pipeline of pharmaceutical products and vaccines in various stages of development. The company actively engages in strategic collaborations, including a partnership with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research alliance with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and licensing option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company officially rebranded as Sanofi in May 2011, having previously operated under the name Sanofi-Aventis.